Pipeline

---

GRIK Therapeutics has lead candidate, GRIK0002, in pre-clinical development for rare pediatric, genetically driven, drug-resistant and common epilepsies. The lead molecule has shown promising pharmacological and efficacy results with plans to file for IND. 

Additional programs in neurology and psychiatric indications are in discovery phase as well as a cardiac program.